Search

Displaying results 721 - 730 of 10000 in total
  1. Drug

    Racepinephrine

    go.drugbank.com/drugs/DB11124
    Approved

    It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride. … It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath.

    Mixtures: Gingibraid W Epineph and Alum 1e, Gingibraid W Epineph and Alum 2eCategories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  2. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent

    Categories: Melanocortin Receptor Agonists, Melanocortin 1 Receptor (MC1-R) Agonists
  3. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    The dextrorotary form of xylose, D-xylose, refers usually to the endogenously occurring form of the sugar in living things. The levorotary form, L-xylose, can refer to the form that is synthesized. … Xylose has also been used as a diagnostic agent to observe malabsorption. Reduction of xylose by catalytic hydrogenation produces the common food additive sweetener substitute xylitol [DB11195].

  4. Drug

    Calcium citrate

    go.drugbank.com/drugs/DB11093
    ApprovedInvestigational

    Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements.

    Mixtures: Cal-mag (one To One) With Potass & Zinc, Re Ob 90 DHA
  5. Drug

    Carbon monoxide

    go.drugbank.com/drugs/DB11588
    ApprovedInvestigational

    The DLCO measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. The DLCO test is both convenient and simple for the patient to undergo. … to prevent the growth of microorganisms [L2538].

    Mixtures: Co-HE-O2-N2 Mixture, Co-NE-O2-N2 Mixture
  6. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    [A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart … uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).

    Mixtures: PIOGLITAZONE E METFORMINA EG, PIOGLITAZONE E METFORMINA EGCategories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity
  7. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718] … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell

  8. Drug

    Nicotine

    go.drugbank.com/drugs/DB00184
    ApprovedInvestigational

    It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission.

  9. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    Categories: Orexin Receptor Antagonists
  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors